Cardiff Oncology (CRDF)
1.53
+0.03 (2.00%)
Upcoming Events
Latest Headlines
Craig-Hallum Downgrades Cardiff Oncology (CRDF) to Hold
June 3, 2026 11:58 AM - StreetInsider
Form 8-K Cardiff Oncology, Inc. For: Jun 03
June 3, 2026 8:30 AM - SEC Filing
Cardiff Oncology reports positive phase 2 trial results for cancer drug
June 2, 2026 9:06 AM - StreetInsider
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
June 2, 2026 9:06 AM - Globe NewsWire
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
June 1, 2026 4:01 PM - Globe NewsWire
H.C. Wainwright Downgrades Cardiff Oncology (CRDF) to Neutral
June 1, 2026 6:41 AM - StreetInsider
TD Cowen Downgrades Cardiff Oncology (CRDF) to Hold
June 1, 2026 6:14 AM - StreetInsider
Form 8-K Cardiff Oncology, Inc. For: May 27
May 29, 2026 5:11 PM - SEC Filing
Cardiff Oncology schedules webcast for updated trial data
May 21, 2026 5:00 PM - StreetInsider
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
May 21, 2026 5:00 PM - Globe NewsWire
Cardiff Oncology sues Nerviano Medical Sciences over license dispute
May 19, 2026 5:03 PM - StreetInsider
Form 8-K Cardiff Oncology, Inc. For: May 19
May 19, 2026 5:01 PM - SEC Filing
Cardiff Oncology, Inc. (CRDF) Misses Q1 EPS by 5c
May 14, 2026 4:21 PM - StreetInsider
Form 8-K Cardiff Oncology, Inc. For: May 14
May 14, 2026 4:16 PM - SEC Filing
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
May 14, 2026 4:10 PM - Globe NewsWire
Form 10-Q Cardiff Oncology, Inc. For: Mar 31
May 14, 2026 4:01 PM - SEC Filing
Form 4 Cardiff Oncology, Inc. For: Apr 27 Filed by: Aggarwal Ajay
April 28, 2026 6:14 PM - SEC Filing
Form 3 Cardiff Oncology, Inc. For: Apr 27 Filed by: Aggarwal Ajay
April 28, 2026 6:11 PM - SEC Filing
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2026 4:01 PM - Globe NewsWire
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
April 27, 2026 7:00 AM - Globe NewsWire
Form DEFA14A Cardiff Oncology, Inc.
April 23, 2026 7:12 PM - SEC Filing
Form ARS Cardiff Oncology, Inc. For: Dec 31
April 23, 2026 7:12 PM - SEC Filing
Form DEF 14A Cardiff Oncology, Inc. For: Jun 11
April 23, 2026 7:12 PM - SEC Filing
Cardiff Oncology to present cancer drug trial data at ASCO meeting
April 21, 2026 10:00 AM - StreetInsider
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
April 21, 2026 10:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Cardiff Oncology (CRDF)
April 20, 2026 6:39 AM - StreetInsider
Cardiff Oncology presents preclinical data on cancer drug combination
April 17, 2026 4:01 PM - StreetInsider
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
April 17, 2026 4:01 PM - Globe NewsWire
Form 3 Cardiff Oncology, Inc. For: Apr 06 Filed by: Muntner Joshua B
April 16, 2026 8:08 PM - SEC Filing
Form 4/A Cardiff Oncology, Inc. For: Apr 06 Filed by: Muntner Joshua B
April 16, 2026 8:07 PM - SEC Filing
Form 4 Cardiff Oncology, Inc. For: Apr 14 Filed by: Smeal Tod
April 16, 2026 4:04 PM - SEC Filing
Form 4 Cardiff Oncology, Inc. For: Apr 06 Filed by: Muntner Joshua B
April 16, 2026 4:01 PM - SEC Filing
Form 8-K Cardiff Oncology, Inc. For: Apr 06
April 9, 2026 4:10 PM - SEC Filing
Cardiff Oncology names Mani Mohindru CEO, adds two executives
April 9, 2026 4:01 PM - StreetInsider
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
April 9, 2026 4:01 PM - Globe NewsWire
Form 4 Cardiff Oncology, Inc. For: Mar 31 Filed by: Mohindru Mani
April 2, 2026 4:17 PM - SEC Filing
Form 8-K Cardiff Oncology, Inc. For: Mar 27
April 2, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G/A Cardiff Oncology, Inc. Filed by: VANGUARD GROUP INC
March 26, 2026 4:42 PM - SEC Filing
Craig-Hallum on Cardiff Oncology (CRDF): KOL Event Reinforces FOLFIRI Synergy
March 26, 2026 11:04 AM - StreetInsider
William Blair stays Outperform on Cardiff Oncology (CRDF) despite adoption hurdles, dilution risks
March 26, 2026 8:48 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Cardiff Oncology (CRDF)
March 26, 2026 6:49 AM - StreetInsider
Cardiff Oncology to present preclinical data on drug combination
March 19, 2026 7:02 AM - StreetInsider
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
March 19, 2026 7:02 AM - Globe NewsWire
Full Article List
